» Articles » PMID: 28446441

Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults During Two Randomized Controlled Trials

Overview
Date 2017 Apr 28
PMID 28446441
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

We investigated the role of AS03 (here AS03), an α-tocopherol oil-in-water emulsion-based adjuvant system, on the long-term persistence of humoral and cell-mediated immune responses to A(H1N1)pdm09 influenza vaccines. In two studies, a total of 261 healthy adults (≤60 years old) were randomized to receive two doses of AS03-adjuvanted vaccine containing 3.75 μg of hemagglutinin (HA) or nonadjuvanted vaccine containing 15 μg of hemagglutinin (in study A) or 3.75 μg of hemagglutinin (in study B) 21 days apart. Hemagglutination inhibition (HI) antibody, memory B-cell, and CD4/CD8 T-cell responses were characterized up to 1 year following dose 1. We also assessed the effects of age and seasonal influenza vaccination history. AS03-adjuvanted (3.75 μg HA) vaccine and nonadjuvanted vaccine at 15 μg but not at 3.75 μg HA elicited HI antibody responses persisting at levels that continued to meet European licensure criteria through month 12. At month 12, the geometric mean titer for AS03-adjuvanted vaccine was similar to that for nonadjuvanted (15-μg) vaccine in study A (1:86 and 1:88, respectively) and higher than that for nonadjuvanted (3.75-μg) vaccine in study B (1:77 and 1:35, respectively). A(H1N1)pdm09-specific CD4 T-cell and B-cell responses were stronger in AS03-adjuvanted groups and persisted only in these groups for 12 months at levels exceeding prevaccination frequencies. Advancing age and a seasonal vaccination history tended to reduce HI antibody and memory B-cell responses and, albeit less consistently, CD4 T-cell responses. Thus, AS03 seemed to enhance the persistence of humoral and cell-mediated responses to A(H1N1)pdm09 vaccine, allowing for antigen sparing and mitigating potential negative effects of age and previous seasonal vaccination. (These studies have been registered at ClinicalTrials.gov under registration no. NCT00968539 and NCT00989287.).

Citing Articles

Flow cytometry as an integrative method for the evaluation of vaccine immunogenicity: A validation approach.

Gianchecchi E, Torelli A, Piu P, Bonifazi C, Ganfini L, Montomoli E Biochem Biophys Rep. 2023; 34:101472.

PMID: 37153861 PMC: 10160688. DOI: 10.1016/j.bbrep.2023.101472.


Nutrition, Immunosenescence, and Infectious Disease: An Overview of the Scientific Evidence on Micronutrients and on Modulation of the Gut Microbiota.

Calder P, Ortega E, Meydani S, Adkins Y, Stephensen C, Thompson B Adv Nutr. 2022; 13(5):S1-S26.

PMID: 36183242 PMC: 9526826. DOI: 10.1093/advances/nmac052.


The role of cell-mediated immunity against influenza and its implications for vaccine evaluation.

Janssens Y, Joye J, Waerlop G, Clement F, Leroux-Roels G, Leroux-Roels I Front Immunol. 2022; 13:959379.

PMID: 36052083 PMC: 9424642. DOI: 10.3389/fimmu.2022.959379.


Functional and Binding H1N1pdm09-Specific Antibody Responses in Occasionally and Repeatedly Vaccinated Healthcare Workers: A Five-Year Study (2009-2014).

Amdam H, Madsen A, Zhou F, Bansal A, Trieu M, Cox R Front Immunol. 2021; 12:748281.

PMID: 34938285 PMC: 8685392. DOI: 10.3389/fimmu.2021.748281.


Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants.

Budroni S, Buricchi F, Cavallone A, Bourguignon P, Caubet M, Dewar V NPJ Vaccines. 2021; 6(1):78.

PMID: 34021167 PMC: 8140094. DOI: 10.1038/s41541-021-00337-0.


References
1.
Uno S, Kimachi K, Kei J, Miyazaki K, Oohama A, Nishimura T . Effect of prior vaccination with a seasonal trivalent influenza vaccine on the antibody response to the influenza pandemic H1N1 2009 vaccine: a randomized controlled trial. Microbiol Immunol. 2011; 55(11):783-9. DOI: 10.1111/j.1348-0421.2011.00381.x. View

2.
Furman D, Hejblum B, Simon N, Jojic V, Dekker C, Thiebaut R . Systems analysis of sex differences reveals an immunosuppressive role for testosterone in the response to influenza vaccination. Proc Natl Acad Sci U S A. 2013; 111(2):869-74. PMC: 3896147. DOI: 10.1073/pnas.1321060111. View

3.
Yang W, Dionne M, Kyle M, Aggarwal N, Li P, Madariaga M . Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial. Vaccine. 2013; 31(40):4389-97. PMC: 7115432. DOI: 10.1016/j.vaccine.2013.07.007. View

4.
Ferguson M, Risi G, Davis M, Sheldon E, Baron M, Li P . Safety and long-term humoral immune response in adults after vaccination with an H1N1 2009 pandemic influenza vaccine with or without AS03 adjuvant. J Infect Dis. 2012; 205(5):733-44. DOI: 10.1093/infdis/jir641. View

5.
Peeters M, Regner S, Vaman T, Devaster J, Rombo L . Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: data from two multicentre randomised trials. Vaccine. 2012; 30(45):6483-91. DOI: 10.1016/j.vaccine.2012.07.081. View